Tuesday, de-extinction company Colossal Biosciences closed a mammoth, $150 million Series B financing round and announced plans to resurrect the iconic Dodo – extinct since the 17th century.

Apogee Therapeutics sprang onto the immunology/inflammatory scene Wednesday heavy on capital but light on salient pipeline details.

The funds, coupled with earlier Series A financing, provide the Indiana-based company with about $150 million in total funding that will support its clinical asset and other developmental programs, according to CEO Kent Hawryluk.

Odyssey Therapeutics raised $168 million in a Series B financing round, which will be used to advance its portfolio of immunomodulators and oncology therapies, according to founder and CEO Gary Glick.